Protagonist Therapeutics saw its stock price target raised to $180 by Barclays following the FDA approval of MIMRYLO, a first-in-class drug for polycythemia vera. The approval was based on strong Phase 3 trial results with 76.9% patient response, triggering a $275 million payment and potential future royalties and milestones up to $875 million from partner Takeda. Takeda will handle sales and further development, allowing Protagonist to focus on other projects while benefiting financially from this milestone.
Medtronic reported Q3 earnings per share of $1.45, surpassing estimates of $1.39, and revenue of $9.76 billion, above the $9.55 billion consensus. The strong financial results reflect broad demand for its cardiovascular devices. The company raised it...
Dell Technologies is expected to report record second-quarter earnings with EPS around $4.91 and revenue near $44.89 billion, fueled by high demand for its AI-optimized servers. This would mark a significant increase from last year's $29.78 billion a...
Science Applications International Corporation (SAIC) saw its price target raised to $154 after reporting Q2 earnings of $3.01 per share, surpassing estimates by over 33%, and revenues of $1.88 billion, beating expectations by 7.52%. The company also...
UBS upgraded Hercules Capital's rating from Neutral to Buy, reflecting confidence in the company's strong financial stability and growth prospects. Hercules Capital, a specialty finance firm supporting tech and life sciences startups, boasts a BBB+ c...
Seeking Alpha's "The Undercovered Dozen" is a weekly series that spotlights 12 lesser-covered stocks with market caps over $100 million and limited recent coverage. The series aims to introduce investors to overlooked investment opportunities, encour...
